TRON Group, Inc. and Nanopharmaceutics, Inc. Announce Definitive Merger Agreement
Retrieved on:
Thursday, August 11, 2022
TRON, Mergers and acquisitions, Tripura Merger Agreement, FINRA, OTC Markets Group, Forward-looking statement, CNS, Ramoplanin, Impression, IV, Cancer, Sale, Notice, Prospectus, Infection, Board, Communication, BCS, Company, Central nervous system, OTC, Securities Act of 1933, Board of directors, News, Consultant, Security (finance), EAGLE
Following consummation of the Merger, TRON will change its name to Nanopharmaceutics, Inc. and will continue to trade on the OTC Pink market.
Key Points:
- Following consummation of the Merger, TRON will change its name to Nanopharmaceutics, Inc. and will continue to trade on the OTC Pink market.
- The merger was unanimously approved by both Boards of Directors of TRON and Nano.
- Immediately prior to the Merger Agreement, TRON entered into an agreement to terminate its common control relationship with Impression VFX Inc., including the extinguishment of a convertible note in exchange for the return of certain assets, and the termination of a service agreement.
- This communication is being made in respect of the merger involving TRON Group, Inc. and Nanopharmaceutics, Inc. TRON Group will file a material event notice with the OTC Pink Market.